Former Chief Financial Officer and Chief Business Officer · Kura Oncology, Inc. (KURA)

Marc Grasso

A named executive officer of Kura Oncology in every fiscal year CompBrief holds from FY2018 to FY2022. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$1,694,717

Salary $45,608Stock awards $309,885

FY2021: $4,356,608

5th of 5 named executive officers at Kura Oncology by FY2022 total.

5 named officers on file for Kura Oncology, FY2022

Marc Grasso’s pay file — $29

  • 5 fiscal years of pay, line by line
  • 7 equity grants, each cited to its filing
  • KURA’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Kura Oncology’s whole pay program stands against its peers

  • Kura Oncology’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on KURA→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 6, 2023 (DEF 14A).

Free

Get Marc Grasso’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Marc Grasso compensation by year

Kura Oncology Summary Compensation Table · all 5 fiscal years held
In US dollars, as Kura Oncology reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2018FY2019FY2020FY2021FY2022
Salary$136,876$387,750$415,000$446,300$45,608
Bonus$100,000$0$0$38,493$0
Stock awards$0$0$0$0$309,885
Option awards$3,288,000$1,481,424$873,160$3,704,925$1,274,353
Non-equity incentive$69,426$152,929$257,300$126,638$0
Pension and deferred compensation$0$0$0$0$0
All other$39,965$90,179$43,648$40,252$64,871
Total$3,634,267$2,112,282$1,589,108$4,356,608$1,694,717

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Kura Oncology, Inc. DEF 14A filed April 6, 2023, accession 0000950170-23-012096, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Kura Oncology, Inc. filed document, accession 0000950170-23-012096. Every figure is read from that document and cited to the page and table it appears in. Filed April 6, 2023.

$3.6M
$2.1M
$1.6M
$4.4M
$1.7M
FY18
FY19
FY20
FY21
FY22
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
Option58,190—$11.86
Option41,667—$19.40
Option37,917—$15.47
Option134,896—$32.80

Per the Outstanding Equity Awards at Fiscal Year-End table in Kura Oncology, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Kura Oncology’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Troy WilsonPresident and Chief Executive Officer$5,304,349
Stephen DaleChief Medical Officer$3,443,477
Kathleen FordChief Operating Officer$2,529,697
Kirsten FlowersFormer Chief Commercial and Corporate Strategy Officer$2,500,538
Marc Grasso · this pageFormer Chief Financial Officer and Chief Business Officer$1,694,717

The full Kura Oncology compensation record

free company brief

This page is one person within Kura Oncology's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Kura Oncology proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Kura Oncology's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Marc Grasso's compensation dossier · One-time report. No refunds.